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Abstract
Background: Mounting evidence suggests that one of the ways that cells adapt to hypoxia is through alternative
splicing. The aim of this study was firstly to examine the effect of hypoxia on the alternative splicing of cancer associated
genes using the prostate cancer cell line PC3 as a model. Secondly, the effect of hypoxia on the expression of several
regulators of splicing was examined.
Methods: PC3 cells were grown in 1% oxygen in a hypoxic chamber for 48 h, RNA extracted and sent for high throughput
PCR analysis at the RNomics platform at the University of Sherbrooke, Canada. Genes whose exon inclusion rate PSI (ψ)
changed significantly were identified, and their altered exon inclusion rates verified by RT-PCR in three cell lines. The
expression of splice factors and splice factor kinases in response to hypoxia was examined by qPCR and western blotting.
The splice factor kinase CLK1 was inhibited with the benzothiazole TG003.
Results: In PC3 cells the exon inclusion rate PSI (ψ) was seen to change by > 25% in 12 cancer-associated genes; MBP,
APAF1, PUF60, SYNE2, CDC42BPA, FGFR10P, BTN2A2, UTRN, RAP1GDS1, PTPN13, TTC23 and CASP9 (caspase 9). The expression
of the splice factors SRSF1, SRSF2, SRSF3, SAM68, HuR, hnRNPA1, and of the splice factor kinases SRPK1 and CLK1 increased
significantly in hypoxia. We also observed that the splice factor kinase CLK3, but not CLK2 and CLK4, was also induced in
hypoxic DU145 prostate, HT29 colon and MCF7 breast cancer cell lines. Lastly, we show that the inhibition of CLK1 in PC3
cells with the benzothiazole TG003 increased expression of the anti-apoptotic isoform caspase 9b.
Conclusions: Significant changes in alternative splicing of cancer associated genes occur in prostate cancer cells in hypoxic
conditions. The expression of several splice factors and splice factor kinases increases during hypoxia, in particular the Cdc-
like splice factor kinases CLK1 and CLK3. We suggest that in hypoxia the elevated expression of these regulators of splicing
helps cells adapt through alternative splicing of key cancer-associated genes. We suggest that the CLK splice factor
kinases could be targeted in cancers in which hypoxia contributes to resistance to therapy.
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Background
Hypoxia is defined as the state in which the availability
or delivery of oxygen is insufficient to meet tissue
demand [1]. It is a common feature of aggressive can-
cers, as angiogenesis cannot match the rate of tumour
growth [2]. Insufficient angiogenesis results in poor
delivery of nutrients, and this coupled with severe hyp-
oxic stress can trigger apoptosis [3]. Remarkably, cancer
cells are often able to survive the harsh conditions asso-
ciated with hypoxia.
Hypoxic tumours are more difficult to treat. In radio-
therapy, high-energy photons directed at the tumour site
react with biological molecules to form DNA-damaging
molecules, causing cancer cells to undergo apoptosis
leading to shrinkage of the tumour [4]. Therefore, in
hypoxic regions where there is a low level of oxygen
molecules, radiotherapy is often not an effective form of
treatment. In addition, tumour hypoxia can lead to
resistance to chemotherapeutic drugs. A review pub-
lished by Brown outlines three reasons for this [5].
Firstly, with diminished vasculature, drugs are unable to
travel to hypoxic regions. Secondly, many chemothera-
peutics target rapidly proliferating cells; however hypoxic
cells tend to progress through the cell cycle much more
slowly. Thirdly, hypoxia increases the expression of pro-
teins involved in drug resistance, such as metallothionein-
IIA (MT-IIA) involved in cisplatin resistance [6] and peri-
ostin involved in arsenic trioxide resistance [7]. A greater
understanding of how tumour cells are able to adapt to
hypoxia could help improve existing therapies or even
suggest new treatment solutions.
Changes in alternative splicing of pre-mRNA may be
one mechanism through which cells are able to adapt to
hypoxic conditions. Pre-mRNA splicing involves the ex-
cision of introns and precise joining of exons to form
the mature RNA [8]. 95% of pre-mRNAs are alterna-
tively spliced in humans [9], giving rise to at least
100,000 distinct proteins [10] despite there only being
an estimated 20,000 protein-coding genes. Splice iso-
forms encode proteins with distinct cellular functions.
Hypoxia has been shown to have a significant effect on
the alternative splicing of genes in normal endothelial
cells [11, 12]; in cartilage endplate-derived stem cells
[13]; in Hep3B liver [14] and in MCF7 breast cancer cell
lines [15]. Hypoxia reduces expression of MAX (MYC-
associated factor X) in endothelial cells through in-
creased unproductive splicing [16]. The splicing of the
SMN2 gene is also modified by hypoxia in the context of
Spinal Muscular Atrophy [17]. While several studies uti-
lised exon arrays to study changes in exonic splicing
during hypoxia, a recent study conducted in MCF7
breast cancer cells utilised whole transcriptome RNA-
seq identifying intron retention as the most commonly
altered alternative splicing event [15].
Given these notable changes in alternative splicing in
hypoxia, the question is which regulators of splicing are
involved? The aim of the present study is firstly to exam-
ine the effect of hypoxia on alternative splicing in a
prostate cancer cell line model, and secondly to examine
the expression of several splice factors and splice factor
in response to hypoxia.
Methods
Cell lines, hypoxia treatments and CLK1 inhibition
The prostate cancer cell lines, PC3 (Sigma-Aldrich,
90112714), VCaP (Sigma-Aldrich, 06020201) and DU145
(ATCC, HTB-81), the normal prostate epithelial PNT2
cell line (ECACC, 95012613), the colorectal cancer cell
line HT29 (Sigma-Aldrich, 91072201), and the breast
cancer cell line MCF7 (Sigma-Aldrich, 86012803) were
cultured in high glucose Dulbecco’s modified Eagle’s
medium (DMEM), supplemented with 10% fetal bovine
serum (FBS) and 1% L-glutamine-penicillin-strepto-
mycin and grown at 37 °C with 5% CO2. Hypoxia was
attained in a modular incubator chamber (MIC-101;
Billups-Rothenberg, USA) using a gas mixture contain-
ing; 1% O2 / 5% CO2 / 94% N2 (BOC, UK). The chamber
was flooded with the hypoxic gas mixture for 2 min and
then sealed and stored in an incubator for 48 h at 37 °C
in 5% CO2. The normoxic control was stored in the
same incubator for the same amount of time. CLK1 was
inhibited with the benzothiazole TG003 (Sigma-Aldrich)
at 10–50 μM; the TG003 stock was dissolved in
dimethylsulphoxide (DMSO).
RNA extraction
RNA was extracted using Tri reagent (Sigma-Aldrich) as
per manufacturer’s instructions with the following modifi-
cations; the first three centrifugations (homogenate, phase
separation and RNA isolation) were conducted at
10,000 g, phase separation centrifugation was for 30 min;
and 0.1 ml chloroform was used for phase separation.
RNA pellets were washed with 0.5 ml 70% ethanol and
centrifuged at 3500 g, and the wash step was repeated
twice. RNA pellets were resuspended in 30 μl nuclease-
free H2O (Promega). Genomic DNA was removed using
the Precision DNase kit (Primerdesign, UK). Total RNA
concentration was determined using a Nanodrop spectro-
photometer (ThermoFisher Scientific, Delaware).
cDNA synthesis and standard PCR
cDNA was synthesised with the GoScript reverse tran-
scription system (Promega, UK). Total RNA was reverse
transcribed using a 1:1 mixture of random primers and
oligo(dT). The GoTaq hot start polymerase kit (Pro-
mega, UK) was used to perform standard PCR. PCR
conditions were: initial denaturation at 94 °C for 2 min;
then 35–40 cycles: 94 °C for 30 s; 58 °C for 30 s; and
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72 °C for 30 s followed by a final extension at 72 °C for
5 min. Primer sequences used in standard PCR are
shown in Additional file 1: Table S1. PCR products were
run on 2% (w/v) agarose gels for 1 h at 95 V and ana-
lysed using FluorChem Q software, Alpha Innotech
MultiImage III. Optical density peak values were gener-
ated with ImageJ software. Excel was used to calculate
the percentage splicing index (PSI/ψ) where ψ = exon in-
clusion/ exon inclusion + exon skipping band intensities.
High-throughput PCR
High-throughput PCR was performed at the RNOmics
platform at the University of Sherbrooke, Canada. RNA
integrity was determined using an Agilent 2100 Bioana-
lyzer (Agilent Technologies). 2.2 μg total RNA were
reverse transcribed with Transcriptor reverse transcript-
ase, random hexamers, dNTPs (Roche Diagnostics), and
10 units of RNAse OUT (Invitrogen) in 20 μl. All
primers were resuspended in 20–100 μM stock solutions
in Tris-EDTA buffer (IDT) and diluted as primer pairs
to 1.2 μM in RNase and DNase-free water (IDT). RT-
PCR reactions were performed using 10 ng cDNA as
template in a 10 μL final volume containing 0.2 mmol/L
dNTP, 1.5 mmol/L MgCl2, 0.6 μmol/L each primer, and
0.2 units of Platinum Taq DNA polymerase (Invitrogen).
After an initial denaturation at 95 °C for 2 min, 35 PCR
cycles were performed; 94 °C 30 s, 55 °C 30 s, and 72 °C
60 s, followed by a final extension step at 72 °C for
2 min. PCR reactions were carried out on the GeneAmp
PCR System 9700 (ABI), and the amplicons were exam-
ined by automated microcapillary electrophoresis using
Caliper LC-90 instruments (Caliper LifeSciences). The
percent spliced index (PSI, ψ) was calculated as the ratio
of the band intensity of the exon inclusion amplicon
divided by the sum of both inclusion and exclusion
amplicon band intensities, measured using ImageJ soft-
ware. The selection of cassette exons was based on genes
from the NCBI RefSeq database associated with cancer
and apoptosis pathways, all of which suitable for PSI
analysis [18, 19].
qRT-PCR
qRT-PCR was performed in 96-well plates as per the
protocol by Primerdesign (UK), using SensiFAST Sybr
Hi-Rox kit (Bioline, UK) mastermix. Three technical
repeats were conducted per experimental sample, and
nuclease free water was used as a negative control.
qRT-PCR plates were run on an ABI 7300 qRT-PCR
thermal cycler (Applied Biosciences). PCR conditions
were as follows; initially 95 °C for 10 min; then 95 °C for
15 s; 60 °C for 1 min for 40 cycles. Melting curve condi-
tions were 95 °C for 15 s; 60 °C for 1 min; 95 °C for 15 s.
Primer sequences used in qRT-PCR are shown in
Additional file 2: Table S2. CT values were normalised to
the UBC and RPL13A housekeeping genes. All results
were calculated using Excel software (Microsoft, USA).
Fig. 1 Exposure of PC3 cells to hypoxia (1% oxygen) results in changes in alternative splicing of cancer associated genes. PC3 prostate cancer cells
were exposed to 1% oxygen or normoxic conditions for up to 48 h. a Protein samples were extracted at 24 and 48 h time points and western blotted
for CA IX (carbonic anhydrase 9), a hypoxia marker; N refers to normoxia and H to hypoxia. β-actin was used as a loading control. b RNA samples were
extracted at 48 h and sent to the RNomics platform at the University of Sherbrooke, Canada, for high-throughput PCR analysis of the rate of inclusion
of 600 cancer-associated cassette exons. Genes whose ψ indexes (proportion of exon included) changed by > 25% are listed
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Protein extraction and quantification
For the extraction of protein, cells were washed with
phosphate buffered saline (PBS) before the addition
RIPA lysis buffer (Sigma, UK) and phosphatase inhibitor
tablets (Complete Mini EDTA-free PI tablets, Roche
Diagnostics, UK). Cell lysates were collected in 1.5 ml
Eppendorf tubes and kept on ice. The Pierce BCA assay
(Thermo Fisher Scientific, USA) was used to measure
protein concentration.
Western blotting
Protein samples were mixed 1:1 with 2× Laemmli buffer
(Sigma, UK) and incubated at 100 °C for 5 min before be-
ing chilled on ice. Protein samples of equal amounts were
subjected to SDS-PAGE and transferred to PDVF mem-
branes. Membranes were incubated at 4 °C overnight with
one of the following antibodies; anti-CA IX (M75 mono-
clonal antibody, Novus Biologicals); anti-SRSF1 (sc-33652,
SantaCruz Biotechnology, UK); anti-CLK1 (R1471–1 s,
Abiocode, USA); anti-phospho SR(1H4) (sc-13509, Santa-
Cruz Biotechnology, UK); anti-β-actin (ab8226, Abcam,
UK). Horse anti-mouse IgG HRP-linked antibody (7076S,
Cell Signalling, UK) was used to detect all antibodies apart
from anti-CLK1, which was detected by goat anti-rabbit
IgG HRP-linked antibody (7074, Cell Signalling, UK).
Laminata Forta Western HRP substrate (Millipore, UK)
was used to image protein bands.
Analysis of promoter sequences
The promoter sequences of SRSF1, SRSF2, SRSF3,
SAM68, HuR, hnRNP A1, CLK1 and SRPK1 splice fac-
tors and splice factor kinases were examined for the
presence of HIF response element (HRE) sequences (5’-
RCGTG-3′) using the Eukaryotic Promoter Database
(http://epd.vital-it.ch/). Parameters were set from − 1000
to + 100 of the transcription start site (TSS), as HIF-1α
mostly binds close to the TSS [20].
Statistical analysis
All data obtained for the standard and qRT-PCR experi-
ments was subjected to Shapiro-Wilks and Bartlett’s test
in order to deduce the distribution and variance of the
data, respectively. For the standard PCR, data that was
found to be normally distributed and homoschedastic
was then subjected to a student’s T-test in order to
examine the statistical significance of the data. Results
found not to be normally distributed and/or heterosche-
dastic were subjected to a Mann Whitney U statistical
Table 1 List of genes whose ψ value change by over 25% in hypoxia
Gene name Gene function Function of splice isoform Change in splice
isoform expression after hypoxia
APAFl Required for the formation of the apoptosome
in apoptosis [32]
Exon 17a codes for a WDR domain required
for the formation of the apoptosome [33]
Exon 17a skipping is favoured
in hypoxia
BTN2A2 Involved in immune tolerance in cancer Exon 5 skipping forms a truncated protein that
negatively regulates the full length protein
involved in immune tolerance [39]
Increased exon inclusion, which
promotes immune tolerance
CDC42BPA Reorganisation of the cytoskeleton, formation
of filopodia and assignment of cellular polarity.
Implicated in cancer cell motility and invasion
Unknown function Decrease in exon inclusion in
hypoxia.
FGFR10P Ciliogenesis, cellular motility, cell growth and
cell cycle progression
Unknown function Exon skipping favoured in
hypoxia
MBP Formation of the myelin sheath. Elevated in
breast cancer and lung cancer patients with
brain metastasis
Unknown function. Exon skipping favoured in
hypoxia.
PTPN13 Competing roles as a tumour suppressor
and oncogene
Unknown function. Decrease in exon inclusion in
hypoxia
PUF60 Modulates alternative splicing through
recognition of 3′ splice sites. Regulates
c-myc transcription
Exon 5 skipping results in expression of an isoform
known as FIR, a c-myc repressor [40, 41]
Expression of anti-oncogenic
FIR isoform favoured in hypoxia.
RAP1GDS1 Activates multiple small GTPases in the Rho
and Ras families
Exon 5 skipping produces SmgGDS-558 which
plays a greater role in proliferation and NFkB
activity than the full-length SmgGDS-607 splice
variant [42]).
Hypoxia favours the smgGDS-
558 isoform.
SYNE2 Influences the shape and migration properties
of cells
Exon 107 encodes a domain required for scaffolding
for protein-protein interactions [43].
Exon skipping favoured in
hypoxia
TTC23 Unknown function but expression linked to
cervical, bladder and prostate cancers.
Unknown function Exon inclusion favoured in
hypoxia.
UTRN Maintenance of the cytoskeleton Unknown function Exon skipping increased in
hypoxia.
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test of significance. A Mann Whitney U non-parametric
test was used for test for statistical significance for all
the real-time PCR data. For all results obtained from the
standard PCR and real-time PCR experiments, the
means were calculated from the results and plotted on
graphs, and error bars were added using the 95% confi-
dence interval.
Results
High-throughput PCR analysis of alternative splicing in
hypoxic PC3 cells
It is clear that cells can adapt to hypoxic conditions by
altering alternative splicing programmes [11–17]; how-
ever the effect of hypoxia on alternative splicing in pros-
tate cancer cells has not been examined. We utilised a
hypoxic chamber, perfused with an air mixture contain-
ing 1% oxygen, and exposed PC3 cells (androgen inde-
pendent, established from a grade 4 prostatic
adenocarcinoma) to these conditions for up to 48 h. To
confirm the establishment of a hypoxic environment we
measured the hypoxia marker carbonic anhydrase IX
(CA IX). CA IX is highly induced in hypoxia as it facili-
tates the adaptation of cells to a severely altered pH en-
vironment [21]. Consistent with hypoxic conditions a
significant induction of CA IX was observed (Fig. 1a).
RNA was extracted from PC3 cells 48 h after seeding,
one set of cells growing in normoxia and another in 1%
oxygen for 48 h. The RNA was sent for analysis at the
RNOmics platform at the University of Sherbrooke,
Canada. The RNOmics platform utilises a high-
throughput reverse transcription-PCR platform to ana-
lyse cassette exon events associated with 600 cancer-
associated genes; the approach is called LISA (Layered
and Integrated system for Splicing Annotation) [18, 19].
Cassette exon inclusion is measured as the value PSI (ψ)
where 1 = complete inclusion, and 0 complete exon skip-
ping. Out of the LISA data set we found that 11 genes
showed a change in ψ value greater than 25% compared
to normoxic values (Fig. 1b; MBP, APAF1, PUF60,
SYNE2, CDC42BPA, FGFR10P, BTN2A2, UTRN,
RAP1GDS1, PTPN13, and TTC23). We note that several
of the genes are involved in the regulation of cytoskeletal
Fig. 2 Verification of high-throughput PCR results. RNA was extracted from PC3 (N = 5) and VCaP (N = 3) prostate cancer, and PNT2 (N = 3) normal
prostate epithelium cell lines after 48 h in normoxia or 1% in hypoxia. For each gene a representative PCR is shown, together with the cassette
exon involved. The average splicing index ψ (proportion of exon included) is shown graphically. The genes areMBP, APAF1, PUF60 and SYNE2
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architecture. The properties of the alternative splice iso-
forms are summarised in Table 1.
Verification of high-throughput PCR results
In order to validate the LISA results the experiment
was repeated in three cell lines. In each case an
equivalent number of PC3 and DU145 prostate cancer
cells and the normal epithelial cell line PNT2 were
exposed to 1% oxygen for 48 h. CA IX levels were el-
evated in each repeat experiment (data not shown).
RNA was extracted and cDNA synthesized, and PCR
performed using the same primers used in the RNO-
mics platform high-throughput PCR assay (Additional
file 1: Table S1). To the set of 11 genes from the
LISA analysis, we added CASP9 (caspase-9), an im-
portant apoptosis marker (not present in the Sher-
brooke LISA gene set). CASP9 expresses several
splice isoforms. Caspase 9b arises from skipping of
exons 3–6, resulting in a truncated, anti-apoptotic
isoform, whereas caspase 9a includes exons 3–6
encoding the functional pro-apoptotic isoform.
Changes in ψ were statistically consistent in PC3
cells, confirming the findings of the high-throughput
PCR. Quantification of PCR bands using Image J was
performed for each of the repeats and a representa-
tive PCR gel is shown in each case (Figs. 2, 3, and 4).
Expression of splice factor kinases in hypoxic PC3 cells
Changes in alternative splicing in hypoxia are likely
to arise from changes in the expression and activity
of splice factors and of splice factor kinases that
modulate their function. We began by selecting a set
of splice factors that have been shown to be associ-
ated with abnormal splicing patterns in cancer. These
include three SR (serine- arginine rich) proteins
SRSF1 (a proto-oncogene [22]), SRSF2 and SRSF3; the
splice factor SAM68 (involved in signal transduction),
HuR and hnRNPA1; and the splice factor kinases
CLK1 and SRPK1. Several publications have identified
a core hypoxia inducible factor (HIF) response
Fig. 3 Verification of high-throughput PCR results. RNA was extracted from PC3 (N = 5) and VCaP (N = 3) prostate cancer, and PNT2 (N = 3) normal
prostate epithelium cell lines after 48 h in normoxia or 1% in hypoxia. For each gene a representative PCR is shown, together with the cassette
exon involved. The average splicing index ψ (proportion of exon included) is shown graphically. The genes are CDC42BPA, FGFR10P, BTN2A2, UTRN
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element that is conserved from animals to zebrafish
(5’-RCGTG-3′). Therefore, we examined their pro-
moter sequences using the eukaryotic promoter data-
base with parameters set from − 1000 to + 100 of the
transcription start site, and noticed the presence of
1–5 HIF binding sites (Fig. 5a). HIF binding sites
were present in all gene promoters except for the
splice factor kinase SRPK1 (Fig. 5a). Next we exam-
ined their expression in hypoxia using qRT-PCR. The
expression of all splice factor and splice factor kinases
appeared to increase in hypoxia (Fig. 5b). Given that
CLK1 has previously been shown to be HIF-inducible
[23] we confirmed its increased expression, along with
its substrate the splice factor SRSF1 by western blot
(Fig. 5c). We also used a monoclonal antibody,
mAb104, that specifically recognises phosphorylated
SR proteins [24] and noticed elevated phosphorylation
of SR proteins in hypoxia, consistent with an in-
creased activity of splice factor kinases (Fig. 5d).
Induction of CLK family expression in hypoxia
We examined the expression of the CLK (CDC-like)
splice factor kinase CLK1 in more detail. The CLK
family comprises four genes in humans, termed
CLK1–4. Among these, CLK1 and CLK4 are very
similar in amino-acid sequence. CLK1, CLK2 and
CLK4 are ubiquitously expressed, whereas CLK3 is
most expressed in testis [25]. Among the CLKs,
CLK1 is the most highly studied, and its interaction
with its substrate SRSF1 is well understood [26].
Firstly we looked at the induction of CLK1, and for
comparison CLK3 in PC3 cells in three different
hypoxic conditions, 1.0%, 0.2% and 0.0% oxygen. We
observed an induction of CLK1 in all three hypoxic condi-
tions after 16 h (Fig. 6a); unexpectedly, we also observed
that CLK3 was induced. For comparison, Affymetrix micro-
array experiments were performed on DU145 prostate,
HT29 colorectal and MCF7 breast cancer cell lines
exposed to 0.0% hypoxia [27]. We wanted to determine
Fig. 4 Verification of high-throughput PCR results. RNA was extracted from PC3 (N = 5) and VCaP (N = 3) prostate cancer, and PNT2 (N = 3) normal
prostate epithelium cell lines after 48 h in normoxia or 1% in hypoxia. For each gene a representative PCR is shown, together with the cassette exon
involved. The average splicing index ψ (proportion of exon included) is shown graphically. The genes are RAP1GDS1, PTPN13, TTC23 and CASP9
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whether or not CLK induction during hypoxia is specific to
PC3 prostate cancer cells. We observed strong induction of
CLK1 and CLK3 in all three cell lines, but not CLK2 and
CLK4 (Fig. 6b). Finally, we inhibited CLK1 activity in PC3
cells using the benzothiazole inhibitor TG003 [28] in order
to determine the effect on CASP9 alternative splicing. We
found that the expression of caspase 9b, clearly reduced
in hypoxia (Fig. 4c), increased following CLK1 inhibition
(Fig. 6c).
Discussion
Recently there has been interest in examining hypoxia-
driven changes in alternative splicing. A genome-wide
study was conducted in hypoxic endothelial cells using
the Affymetrix human exon 1.0 array [12]. Alterations
were found in 294 genes including nine alternative
splicing events that were not previously related to hyp-
oxia. The changes involved to a large extent genes
involved in angiogenesis, glucose metabolism, cell cycle,
DNA repair, and cytoskeletal remodelling. In the DNA
damage response, hypoxia drives the alternative splicing
of genes towards noncoding isoforms through increased
intron retention [29]. In a similar vein, in endothelial
cells hypoxia promotes the expression of a splice isoform
of MAX (Myc associated factor X) that is degraded by
nonsense-mediated decay, and another splice isoform
that encodes an unstable protein; the net effect is less
active MAX protein is produced [16]. Investigations
using the Hep3B hepatocarcinoma cell line revealed the
hypoxia altered alternative splicing patterns of HIF and
non-HIF genes including CA IX, RAP1GDS1 and MBP
[14]; MBP was also identified in our high throughput
PCR screen (Fig. 1b). In MCF7 breast cancer cells
hypoxia was found to affect the alternative splicing of
genes that are involved in a number of cancer-driving
processes including angiogenesis, cell growth and
Fig. 5 Changes in the expression of splice factors and splice factor kinases in response to hypoxia. a This panel illustrates the presence of
potential hypoxia inducible factor (HIF) binding sites in the promoters of six splice factor (SRSF1, SRSF2, SRSF3, SAM68, HuR, hnRNPA1) and two
splice factor kinase genes (CLK1, SRPK1), orange boxes. b Quantitative PCR measurement of splice factor and splice factor kinase expression, PC3
cells in normoxia or hypoxia for 48 h. The housekeeping gene was UBC. c Western blot confirming increased levels of CLK1 and its substrate
SRSF1 in hypoxia (PC3 cells, 48 h at 1% oxygen). β-actin is the loading control. d Levels of phosphorylated SR proteins measured with the mAb104
antibody that preferentially binds phosphorylated SR proteins
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apoptosis, suggesting that hypoxia plays a role in cancer
progression [15]. Furthermore, the latter study also con-
firmed intron retention as the most common type of
splicing event to be altered in hypoxia. Typically, intron
retention can result in the use of a premature stop
codon, which in turn can trigger nonsense mediated
decay (NMD) or produce a truncated protein. Thus
there are a number of clearly documented cases of cells
adapting to hypoxia by changing alternative splicing of
key genes [11–17]. In the present study we can confirm
that changes in alternative splicing of cancer genes also
occur in response to hypoxia in the widely used prostate
cancer cell lines PC3 and VCaP, and in the normal
epithelial cell line PNT2.
Hypoxic tumour cells can become resistant to apoptosis
by expressing apoptosis inhibitors such as IAP-2 [30].
There are several components of the apoptosis machinery
and genes express pro- or anti-apoptotic splice isoforms
(BCL2L1, MCL1, CASP9 and APAF1 are notable exam-
ples). A recent study shows that the pharmacological
inhibition of APAF1 allows cells in which apoptosis is
induced by hypoxia to recover [31–33]. We examined the
alternative splicing of CASP9, and noted that in hypoxia
expression of the pro-apoptotic full length caspase 9a
isoform increased significantly in PC3 and PNT2 cells
(Fig. 4c). We suggest that changes in alternative splicing
in hypoxia result in a different balance of splice isoforms
that contribute to the induction of apoptosis.
We examined the promoters of a representative set of
splice factors and splice factor kinases, and found putative
HIF consensus binding sites in 7/8 (the exception being
SRPK1). The expression of all eight splice factors and ki-
nases appeared to increase in hypoxia, suggesting a gen-
eral activation of the machinery of alternative splicing in
conditions of severe hypoxic stress. We turned our atten-
tion to the CDC-2 like (CLK) family of splice factor ki-
nases, because recent literature has identified an increase
in expression of CLK1 in response to hypoxia [23, 34]. We
confirmed the induction of CLK1, not just in PC3 cells,
but also in another prostate cancer cell line, DU145, and
in HT29 colorectal and MCF7 breast cancer cell lines (Fig.
6a and b). We observed the parallel induction of CLK1
and CLK3 in the four cell lines. CLK3 is best known for
its expression in normal testis [25]; however we suggest
that along with CLK1, CLK3 might contribute to adapta-
tion to hypoxia in cancer cells.
To address the functional significance of CLK1 induc-
tion in the context of alternative splicing in hypoxia, we
treated PC3 cells with the CLK1 inhibitor, the benzothia-
zole TG003 [28]. Inhibition of CLK1 with up to 50 μM
TG003 increased the expression of caspase 9b, the anti-
apoptotic isoform in which exons 3–6 are skipped (Fig.
Fig. 6 Changes in the expression of the CLK family of splice factor kinases in response to hypoxia and the effect of CLK1 inhibition on caspase 9
splicing. a PC3 cells were exposed for 16 h to three different hypoxic conditions; 1.0%, 0.2% and 0.0% oxygen and N (normoxia). The relative
expression of CLK1 and of its homologue CLK3 are shown, normalised to the housekeeping gene RPL31A. b PC3 cells were treated for 48 h with
the CLK1 inhibitor TG003; the effect on alternative splicing of CASP9 is shown. c Microarray time-course showing the expression of four CLKs over
24 h in 0% hypoxia in DU145 (prostate), HT29 (colon) and MCF7 (breast) cancer cell lines
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6c). There is interest in the potential of targeting CLK1
in the context of the influenza [35] and HIV-1 viruses
[36] and in cancer cells [37, 38]. The fact that CLK ki-
nases appear to help cancer cells adapt to hypoxia sug-
gests that they could be useful therapeutic targets.
Conclusions
This study demonstrates that there are significant
changes in exon inclusion rates in a range of cancer-
associated genes in PC3 prostate cancer cells exposed to
1% oxygen hypoxic conditions. The expression of splice
factors and splice factor kinases also increases signifi-
cantly in hypoxia; in particular we observed a consistent
induction of CLK1 and CLK3 in four independent cell
lines. We suggest that targeting CLK kinases may pro-
vide benefit in the treatment of cancers in which tumour
hypoxia contributes to resistance to therapy.
Additional file
Additional file 1: Table S1. Forward (F) and reverse (R) primer sequences
for all human genes amplified using standard PCR. The target sites of the
primers, including the exonic locations, are indicated. (DOCX 13 kb)
Additional file 2: Table S2. Forward and reverse primer sequences for
all human genes amplified using qRT-PCR. Details of the primers using in
qRT-PCR analysis. (DOCX 13 kb)
Abbreviations
CLK: cdc-like kinase; HIF: Hypoxia inducible factor; SR: Serine-arginine rich
Acknowledgments
We are very grateful to Professor Silvia Pastorekova for hosting EB in her
laboratory and providing valuable expertise in setting up hypoxia experiments.
We are very grateful to Professor Masatoshi Hagiwara for advice on CLK1
inhibition. We would also like to thank David Corry for valuable technical
assistance. ML is a member of the European Organisation for Research and
Treatment of Cancer (EORTC) Pathobiology group.
Funding
This study was supported by a PhD bursary to EB awarded by the University
of the West of England, Bristol, through Quality Research (QR) funds.
Availability of data and materials
The authors are happy to share all data and pertinent materials.
Authors’ contributions
All authors have read and approved the manuscript. EB performed the
hypoxia experiments, PCR verifications, and the analysis of splice factor
expression with input from SP and SU. PT, MD and EL produced the high-
throughput PCR data. RK performed the in-depth analysis of CLK expression.
IW and JH contributed to the supervision of EB. ML was the principal
investigator.
Ethics approval
Not applicable.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Centre for Research in Biosciences, Faculty of Health and Applied Sciences,
University of the West of England, Coldharbour Lane, Frenchay, Bristol BS16
1QY, UK. 2Z8 Pavillon de Recherche Appliquée sur le Cancer (PRAC),
Université de Sherbrooke, 3201 Jean-Mignault, Sherbrooke, Québec J1E 4K8,
Canada. 3Department of Radiation Oncology (Maastro Lab), GROW-School for
Oncology and Developmental Biology, Maastricht University, Maastricht, The
Netherlands.
Received: 21 July 2017 Accepted: 15 March 2018
References
1. Loboda A, Jozkowicz A, Dulak J. HIF-1 versus HIF-2—is one more important
than the other? Vasc Pharmacol. 2012;56:245–51.
2. Evans SM, Koch CJ. Prognostic significance of tumor oxygenation in
humans. Cancer Lett. 2003;195:1–16.
3. Semenza G. HIF-1: mediator of physiological and pathophysiological
responses to hypoxia. J Appl Physiol. 2000;88:1474–80.
4. Grimes DR, Partridge M. A mechanistic investigation of the oxygen fixation
hypothesis and oxygen enhancement ratio. Biomed Phys Eng Express. 2015;
1:045209.
5. Brown JM. The hypoxic cell: a target for selective cancer therapy —eighteenth
Bruce F. Cain memorial award lecture. Cancer Res. 1999;59:5863–70.
6. Murphy BJ, Laderoute KR, Chin RJ, Sutherland RM. Metallothionein IIA is up-
regulated by hypoxia in human A431 squamous carcinoma cells. Cancer
Res. 1994;54:5808–10.
7. Liu Y, Gao F, Song W. Periostin contributes to arsenic trioxide resistance in
hepatocellular carcinoma cells under hypoxia. Biomed Pharmacother. 2017;
88:342–8.
8. Zhou Z, Fu XD. Regulation of splicing by SR proteins and SR protein-specific
kinases. Chromosoma. 2013;122:191–207.
9. Pan Q, Shai O, Lee LJ, Frey BJ, Blencowe BJ. Deep surveying of alternative
splicing complexity in the human transcriptome by high-throughput
sequencing. Nat Genet. 2008;40:1413–5.
10. Biamonti G, Bonomi S, Gallo S, Ghigna C. Making alternative splicing
decisions during epithelial-to-mesenchymal transition (EMT). Cell Mol Life
Sci. 2012;69:2515–26.
11. Hang X, Li P, Li Z, Qu W, Yu Y, Li H, et al. Transcription and splicing
regulation in human umbilical vein endothelial cells under hypoxic stress
conditions by exon array. BMC Genomics. 2009;10:126.
12. Weigand JE, Boeckel JN, Gellert P, Dimmeler S. Hypoxia-induced alternative
splicing in endothelial cells. PLoS One. 2012;7:e42697.
13. Yao Y, Shang J, Song W, Deng Q, Liu H, Zhou Y. Global profiling of the
gene expression and alternative splicing events during hypoxia-regulated
chondrogenic differentiation in human cartilage endplate-derived stem
cells. Genomics. 2016;107:170–7.
14. Sena JA, Wang L, Heasley LE, Hu CJ. Hypoxia regulates alternative splicing of
HIF and non-HIF target genes. Mol Cancer Res. 2014;12:1233–43.
15. Han J, Li J, Ho JC, Chia GS, Kato H, Jha S, et al. Hypoxia is a key driver of
alternative splicing in human breast cancer cells. Sci Rep. 2017;7:4108.
16. Kemmerer K, Weigand JE. Hypoxia reduces MAX expression in endothelial
cells by unproductive splicing. FEBS Lett. 2014;588:4784–90.
17. Bebee TW, Dominguez CE, Samadzadeh-Tarighat S, Akehurst KL, Chandler
DS. Hypoxia is a modifier of SMN2 splicing and disease severity in a severe
SMA mouse model. Hum Mol Genet. 2012;21:4301–13.
18. Venables JP, Koh CS, Froehlich U, Lapointe E, Couture S, Inkel L, et al.
Multiple and specific mRNA processing targets for the major human hnRNP
proteins. Mol Cell Biol. 2008;28:6033–43.
19. Klinck R, Bramard A, Inkel L, Dufresne-Martin G, Gervais-Bird J, Madden R,
et al. Multiple alternative splicing markers for ovarian cancer. Cancer Res.
2008;68:657–63.
20. Schödel J, Oikonomopoulos S, Ragoussis J, Pugh CW, Ratcliffe PJ, Mole DR.
High-resolution genome-wide mapping of HIF-binding sites by ChIP-seq.
Blood. 2011;117:e207–17.
21. Loncaster JA, Harris AL, Davidson SE, Logue JP, Hunter RD, Wycoff CC, et al.
Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of
Bowler et al. BMC Cancer _#####################_ Page 10 of 11
hypoxia: correlations with tumor oxygen measurements and prognosis in
locally advanced carcinoma of the cervix. Cancer Res. 2001;61:6394–9.
22. Karni R, de Stanchina E, Lowe SW, Sinha R, Mu D, Krainer AR. The gene
encoding the splicing factor SF2/ASF is a proto-oncogene. Nat Struct Mol
Biol. 2007;14:185–93.
23. Jakubauskiene E, Vilys L, Makino Y, Poellinger L, Kanopka A. Increased serine-
arginine (SR) protein phosphorylation changes pre-mRNA splicing in
hypoxia. J Biol Chem. 2015;290:18079–89.
24. Zahler AM, Neugebauer KM, Stolk JA, Roth MB. Human SR proteins and
isolation of a cDNA encoding SRp75. Mol Cell Biol. 1993;13:4023–8.
25. Nayler O, Stamm S, Ullrich A. Characterization and comparison of four
serine- and arginine-rich (SR) protein kinases. Biochem J. 1997;326:693–700.
26. Keshwani MM, Hailey KL, Aubol BE, Fattet L, McGlone ML, Jennings PA,
Adams JA. Nuclear protein kinase CLK1 uses a non-traditional docking
mechanism to select physiological substrates. Biochem J. 2015;472:329–38.
27. Starmans MH, Chu KC, Haider S, Nguyen F, Seigneuric R, Magagnin MG, et al.
The prognostic value of temporal in vitro and in vivo derived hypoxia gene-
expression signatures in breast cancer. Radiother Oncol. 2012;102:436–43.
28. Sakuma M, Iida K, Hagiwara M. Deciphering targeting rules of splicing
modulator compounds: case of TG003. BMC Mol Biol. 2015;16:16.
29. Memon D, Dawson K, Smowton CSF, Xing W, Dive C, Miller CJ. Hypoxia-
driven splicing into noncoding isoforms regulates the DNA damage
response. NPJ Genom Med. 2016;1:16020.
30. Dong Z, Wang JZ, Yu F, Venkatachalam M. Apoptosis-resistance of hypoxic
cells. Am J Pathol. 2003;163:663–71.
31. Gortat A, Sancho M, Mondragón L, Messeguer À, Pérez-Payá E, Orzáez M. Apaf1
inhibition promotes cell recovery from apoptosis. Protein Cell. 2015;6:833–43.
32. Bao Q, Lu W, Rabinowitz JD, Shi Y. Calcium blocks formation of
apoptosome by preventing nucleotide exchange in Apaf-1. Mol Cell.
2007;25:181–92.
33. Benedict MA, Hu Y, Inohara N, Núñez G. Expression and functional
analysis of Apaf-1 isoforms. Extra WD-40 repeat is required for
cytochrome c binding and regulated activation of procaspase-9. J Biol
Chem. 2000;275:8461–8.
34. Eisenreich A, Zakrzewicz A, Huber K, Thierbach H, Pepke W, Goldin-Lang P,
et al. Regulation of pro-angiogenic tissue factor expression in hypoxia-
induced human lung cancer cells. Oncol Rep. 2013;30:462–70.
35. Zu M, Li C, Fang JS, Lian WW, Liu AL, Zheng LS, et al. Drug discovery of
host CLK1 inhibitors for influenza treatment. Molecules. 2015;20:19735–47.
36. Wong R, Balachandran A, Mao AYQ, Dobson W, Gray-Owen S, Cochrane A.
Differential effect of CLK SR kinases on HIV-1 gene expression: potential
novel targets for therapy. Retrovirology. 2011;8:47–59.
37. Murar M, Dobias J, Sramel P, Addova G, Hanquet G, Bohac A. Novel CLK1
inhibitors based on N-aryloxazol-2-amine skeleton – a possible way to dual
VEGFR2 TK/CLK ligands. Eur J Med Chem. 2017;126:754–61.
38. ElHady AK, Abdel-Halim M, Abadi AH, Engel M. Development of selective
Clk1 and −4 inhibitors for cellular depletion of cancer-relevant proteins.
J Med Chem. 2017;60:5377–91.
39. Rhodes DA, Stammers M, Malcherek G, Beck S, Trowsdale J. The cluster of
BTN genes in the extended major histocompatibility complex. Genomics.
2001;71:351–62.
40. Kano M, Matsushita K, Rahmutulla B, Yamada S, Shimada H, Kubo S, et al.
Adenovirus-mediated FIR demonstrated TP53-independent cell-killing effect and
enhanced antitumor activity of carbon-ion beams. Gene Ther. 2015;23:50–6.
41. Matsushita K, Kitamura K, Rahmutulla B, Tanaka N, Ishige T, Satoh M,
et al. Haploinsufficiency of the c-myc transcriptional repressor FIR, as a
dominant negative-alternative splicing model, promoted p53-dependent
T-cell acute lymphoblastic leukemia progression by activating Notch1.
Oncotarget. 2015;6:5102.
42. Hauser AD, Bergom C, Schuld NJ, Chen X, Lorimer EL, Huang J, et al. The
SmgGDS splice variant SmgGDS-558 is a key promoter of tumor growth
and RhoA signaling in breast cancer. Mol Cancer Res. 2014;12:130–42.
43. Rajgor D, Mellad JA, Autore F, Zhang Q, Shanahan CM. Multiple novel
nesprin-1 and nesprin-2 variants act as versatile tissue-specific intracellular
scaffolds. PLoS One. 2012;7:e40098.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Bowler et al. BMC Cancer _#####################_ Page 11 of 11
